Biotech Mesoblast has reported strong initial sales of its cell therapy, Ryoncil, its first commercial product since the company was founded two decades ago, sending its shares soaring.

Last December, the US Food and Drug Administration approved the therapy to treat children for complications that could occur during bone marrow transplants, paving the way for the first commercial sales in March.